Back to Search Start Over

Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.

Authors :
Constance JE
Reith D
Ward RM
Balch A
Stockmann C
Korgenski EK
Thorell EA
Sherwin CMT
Source :
Journal of perinatology : official journal of the California Perinatal Association [J Perinatol] 2017 Oct; Vol. 37 (10), pp. 1093-1102. Date of Electronic Publication: 2017 Jun 08.
Publication Year :
2017

Abstract

Objective: To evaluate the risk of nonsteroidal anti-inflammatory drug (NSAID) therapy-associated acute kidney injury (AKI) among neonates diagnosed with patent ductus arteriosus (PDA) who are treated with gentamicin.<br />Study Design: Multicenter retrospective observational study of patients ⩽44 postmenstrual weeks of age diagnosed with PDA who received gentamicin during hospitalization between January 2006 and December 2014. Patients with and without NSAID exposure were matched on covariates associated with AKI and NSAID therapy. The primary end point, AKI, was defined according to Kidney Disease Improving Global Outcomes neonatal criteria.<br />Results: The rate of AKI for the entire cohort (n=594) was 12% (n=71). Among neonates receiving NSAIDS, 14.8% (n=44) experienced an AKI as compared to 9.1% (n=27) for those who were not exposed (relative risk, 1.6; 95% confidence interval, 1.0 to 2.6). Therefore, the attributable risk of NSAID use was 5.7% (95% confidence interval, 0.5 to 11.0).<br />Conclusion: Among neonates with PDA and receiving gentamicin, NSAID therapy increases the risk of AKI by about 6%.

Details

Language :
English
ISSN :
1476-5543
Volume :
37
Issue :
10
Database :
MEDLINE
Journal :
Journal of perinatology : official journal of the California Perinatal Association
Publication Type :
Academic Journal
Accession number :
28594394
Full Text :
https://doi.org/10.1038/jp.2017.80